NeuroBo Pharmaceuticals (NRBO)
(Delayed Data from NSDQ)
$3.88 USD
-0.23 (-5.60%)
Updated Sep 10, 2024 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
NRBO 3.88 -0.23(-5.60%)
Will NRBO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for NRBO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NRBO
The Zacks Analyst Blog Highlights Molina Healthcare, Dr. Reddy's Laboratories and NeuroBo Pharmaceuticals
4 Undervalued Medical Stocks to Buy Amid High Market Volatility
NRBO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Want to Shrug Off Volatility? Buy 3 Medical Growth Stocks
Here's Why NeuroBo Pharmaceuticals, Inc. (NRBO) Could be Great Choice for a Bottom Fisher
Other News for NRBO
NeuroBo Pharmaceuticals GAAP EPS of -$1.85
Buy Rating for NeuroBo Pharmaceuticals Based on Financial Stability and Promising Developmental Pipeline
NRBO Stock Earnings: NeuroBo Pharmaceuticals Misses EPS for Q2 2024
NeuroBo Pharmaceuticals reports Q2 EPS ($1.85), consensus ($1.12)
NeuroBo Completes First Phase 1 Enrollment for Obesity Drug Trial